<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689465</url>
  </required_header>
  <id_info>
    <org_study_id>PTCy-ATG-2018</org_study_id>
    <nct_id>NCT03689465</nct_id>
  </id_info>
  <brief_title>PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis</brief_title>
  <official_title>A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The granulocyte colony-stimulating factor (G-CSF)+antithymocyte globulin (ATG)-based
      protocols and posttransplantation cyclophosphamide (PTCy) protocols have been widely used for
      graft-versus-host disease (GVHD) prophylaxis in haploidentical related donor transplantation
      (haplo-HSCT). Nevertheless, severe acute GVHD remains an obstacle for haplo-HSCT. This study
      is aim to evaluate the efficacy of a modified protocol that includes PTCY and ATG in
      recipients of haplo-HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haploidentical related donor transplantation is now considered an important alternative to
      allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, the strategies for
      graft-versus-host disease (GVHD) prophylaxis mainly include ex vivo and in vivo T-cell
      depletion (TCD) in haploidentical HSCT (haplo-HSCT). In vivo TCD modalities have become
      mainstream including granulocyte colony-stimulating factor (G-CSF)+antithymocyte globulin
      (ATG)-based protocols and posttransplantation cyclophosphamide (PTCy) protocols. The ATG
      strategy has been widely used. Nevertheless, severe acute GVHD remains an obstacle for
      haplo-HSCT. In addition, infections, especially viral infections, remain an important
      drawback of this strategy. This study is aim to evaluate the efficacy of a modified protocol
      that includes PTCY and ATG in recipients of haplo-HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CMV DNAemia</measure>
    <time_frame>1 year posttransplantation</time_frame>
    <description>CMV DNAemia was defined as positive CMV-DNA in the blood when the copies exceeded 500 copies/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aGVHD</measure>
    <time_frame>100 days 1 year posttransplantation</time_frame>
    <description>aGVHD (acute GVHD) was defined according to the 1994 Consensus Conference on Acute GVHD Grading and graded from I to IV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cGVHD</measure>
    <time_frame>2 year posttransplantation</time_frame>
    <description>Chronic GVHD (cGVHD) was graded as limited or extensive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBV DNAemia</measure>
    <time_frame>1 year posttransplantation</time_frame>
    <description>EBV DNAemia was defined as positive EBV-DNA in the blood when the copies exceeded 500 copies/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia relapse</measure>
    <time_frame>2 year posttransplantation</time_frame>
    <description>primary disease relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 year posttransplantation</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>2 year posttransplantation</time_frame>
    <description>disease-free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>PTCy-ATG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.</description>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_label>PTCy-ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX</intervention_name>
    <description>In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.</description>
    <arm_group_label>PTCy-ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.</description>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_label>PTCy-ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin A (CsA)</intervention_name>
    <description>In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.</description>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_label>PTCy-ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate (MTX)</intervention_name>
    <description>In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.</description>
    <arm_group_label>ATG group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient age of 18-65 years

          -  Haploidentical hematopoietic stem cell transplant recipient

          -  Subjects (or their legally acceptable representatives) must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study

        Exclusion Criteria:

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Lin, M.D.</last_name>
    <phone>+86-020-62787883</phone>
    <email>lansinglinren@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ren Lin, MD</last_name>
      <phone>+86-020-61641613</phone>
      <email>lansinglinren@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qifa Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shunqing Wang</last_name>
    </contact>
    <investigator>
      <last_name>Shunqing Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danian Nie</last_name>
    </contact>
    <investigator>
      <last_name>Danian Nie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dongjun Lin</last_name>
    </contact>
    <investigator>
      <last_name>Dongjun Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yajing Xu</last_name>
    </contact>
    <investigator>
      <last_name>Yajing Xu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chenzhou First People's Hospital</name>
      <address>
        <city>Chenzhou</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinquan Liang</last_name>
    </contact>
    <investigator>
      <last_name>Xinquan Liang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wang Yu</last_name>
    </contact>
    <investigator>
      <last_name>Xiaojun Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang Y, Fu HX, Liu DH, Xu LP, Zhang XH, Chang YJ, Chen YH, Wang FR, Sun YQ, Tang FF, Liu KY, Huang XJ. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2014 Mar;49(3):426-33. doi: 10.1038/bmt.2013.191. Epub 2013 Dec 2.</citation>
    <PMID>24292519</PMID>
  </reference>
  <reference>
    <citation>Chang YJ, Huang XJ. Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant. 2014 Jul;49(7):873-9. doi: 10.1038/bmt.2014.19. Epub 2014 Feb 24. Review.</citation>
    <PMID>24566712</PMID>
  </reference>
  <reference>
    <citation>Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017 Feb;102(2):224-234. doi: 10.3324/haematol.2016.148510. Epub 2016 Dec 7. Review.</citation>
    <PMID>27927772</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>posttransplantation cyclophosphamide</keyword>
  <keyword>antithymocyte globulin</keyword>
  <keyword>viral infection</keyword>
  <keyword>graft-versus-host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

